Lehmann Jan, Retz Margitta, Nürnberg Nils, Schnöckel Uta, Raffenberg Uta, Krams Matthias, Kellner Udo, Siemer Stefan, Weichert-Jacobsen Klaus, Stöckle Michael
Department of Urology, Saarland University, Homburg/Saar, Germany.
Cancer. 2004 Oct 1;101(7):1552-62. doi: 10.1002/cncr.20549.
The American Joint Committee on Cancer and the Union Internationale Contre le Cancer have acknowledged routine laboratory parameters, such as serum calcium, alkaline phosphatase, hemoglobin, and the erythrocyte sedimentation rate (ESR), as predictors of survival in patients with renal cell carcinoma. The predictive value of these parameters compared with proliferation markers, such as Ki-67, proliferating cell nuclear antigen (PCNA), topoisomerase II-alpha, and p100, has not been determined.
Forty-eight consecutive patients who underwent nephrectomy for nonmetastatic renal cell carcinoma between 1990 and 1994 were observed up to 120 months postoperatively. Ten of 48 patients developed tumor progression 6-69 months after surgery. Routine preoperative laboratory parameters as well as tumor-specific data were assessed. Findings were compared with tumor proliferation indices, which were obtained by immunohistochemical staining for nuclear antigens Ki-67, PCNA, topoisomerase II-alpha, and p100 in paraffin embedded tumor tissue.
Univariate and multivariate statistical analyses demonstrated superiority of routine laboratory values compared with tumor proliferation indices in predicting progression-free survival and disease-specific death. The best predictor after tumor size and symptomatic presentation was ESR (P < 0.0001), with ESR values > 70 mm at 2 hours indicating a significantly poorer prognosis. Only the proliferation marker Ki-67 reached univariate significance at a threshold of 7%.
Routine laboratory parameters, such as alkaline phosphatase, lactate dehydrogenase, thrombocyte count, and especially ESR, provided superior long-term prognostic information for patients with nonmetastatic renal cell carcinoma compared with the molecular tumor proliferation markers Ki-67, PCNA, topoisomerase II-alpha, and p100.
美国癌症联合委员会和国际抗癌联盟已认可常规实验室参数,如血清钙、碱性磷酸酶、血红蛋白和红细胞沉降率(ESR),作为肾细胞癌患者生存的预测指标。与增殖标志物(如Ki-67、增殖细胞核抗原(PCNA)、拓扑异构酶II-α和p100)相比,这些参数的预测价值尚未确定。
对1990年至1994年间连续48例行肾切除术治疗非转移性肾细胞癌的患者进行术后长达120个月的观察。48例患者中有10例在术后6 - 69个月出现肿瘤进展。评估术前常规实验室参数以及肿瘤特异性数据。将结果与肿瘤增殖指数进行比较,肿瘤增殖指数通过对石蜡包埋肿瘤组织中的核抗原Ki-67、PCNA、拓扑异构酶II-α和p100进行免疫组织化学染色获得。
单因素和多因素统计分析表明,在预测无进展生存期和疾病特异性死亡方面,常规实验室值优于肿瘤增殖指数。肿瘤大小和症状表现之后,最佳预测指标是ESR(P < 0.0001),2小时时ESR值> 70 mm表明预后明显较差。只有增殖标志物Ki-67在阈值为7%时达到单因素显著性。
与分子肿瘤增殖标志物Ki-67、PCNA、拓扑异构酶II-α和p100相比,常规实验室参数,如碱性磷酸酶、乳酸脱氢酶、血小板计数,尤其是ESR,为非转移性肾细胞癌患者提供了更优的长期预后信息。